This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Marín, F. Articles by Vicente, V. Search for Related Content PubMed PubMed Citation Articles by Marín, F. Articles by Vicente, V.

A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction

Francisco Marín, MD, PhD^*, Rocío González-Conejero, PhD, Kaeng W. Lee, MRCP, Javier Corral, PhD, Vanessa Roldán, MD, PhD, Francisca López, MD^||, Francisco Sogorb, MD^*, Juan Caturla, MD, PhD^||, Gregory Y.H. Lip, MD, FESC, FACC and Vicente Vicente, MD, PhD^,*

^* Cardiology Department, Hospital General Universitario, Alicante, Spain
Centro de Hemodonación, Universidad de Murcia, Murcia, Spain
Haemostasis, Thrombosis, and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, England
Hematology Unit, Hospital de San Vicente, Alicante, Spain
^|| Intensive Care Unit, Hospital General Universitario, Alicante, Spain

View larger version (29K): [in a new window]   Figure 1 (A) Influence in fibrinolytic efficacy of the interaction between smoking habit and factor XIII Val34Leu polymorphism (logistic regression, Enter method, after adjusted by age, gender, cardiovascular risk factors, time delay, and fibrinolytic drug). (B) Influence in outcome at 24 h following fibrinolytic efficacy of the interaction between smoking habit and factor XIII Val34Leu polymorphism (logistic regression, Enter method, after adjusted by age, gender, cardiovascular risk factors, time delay, and fibrinolytic drug). Leu = leucine; OR = odds ratio; val = valine.